Luye Pharma Group Ltd

02186

Company Profile

  • Business description

    Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.

  • Contact

    Hongqiao Road 1438
    22nd Floor, Gubei International Fortune Center II
    Changning District
    Shanghai
    CHN

    T: +86 2153894101

    https://www.luye.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    5,221

Stocks News & Analysis

stocks

Ask the analyst: Where does GYG stand following its US exit?

All roads lead back home for Guzman Y Gomez.
stocks

Chart of the Week: The long term headwinds facing copper shares

The key factors challenging the bull case for copper demand.
stocks

Australia’s oldest REIT undervalued

This REIT remains undervalued as trophy properties shine through.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,048.3074.600.83%
CAC 408,508.0733.210.39%
DAX 4025,779.31198.430.78%
Dow JONES (US)52,900.07594.831.14%
FTSE 10010,679.0326.160.25%
HKSE23,350.03295.001.28%
NASDAQ25,832.67207.36-0.80%
Nikkei 22569,744.071,010.921.47%
NZX 50 Index13,618.4236.230.27%
S&P 5007,483.240.010.00%
S&P/ASX 2008,844.4075.100.86%
SSE Composite Index4,043.6414.740.37%

Market Movers